Subtype
Malignant Biliary Tract Neoplasm
CI-CAN-00003139Explore in graph →
367 active trials6 approved drugs33 evidence items
Loading cancer entity…
Subtype
CI-CAN-00003139Explore in graph →
Clinical trials
1,282 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (152)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07025174 | Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract Cancer(SAIB) | recruiting | Phase 2 | 60 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jun 17, 2025 | clinicaltrials |
| NCT07007832 | Bile Omics for Diagnosing Indeterminate Biliary Strictures | recruiting | — | 260 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER |
| 1 |
| Jun 11, 2025 |
| clinicaltrials |
| NCT06988592 | GemCis Plus PD-1/PD-L1 Inhibitor in Advanced Biliary Tract Cancer: Efficacy and Immune Microenvironment (BTC-IM-1)(BTC-IM-1) | recruiting | — | 100 | Fudan UniversityOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT06277531 | Evaluation of diagnostiC Capacity of eccDNAs as Biomarkers in Indetermined biLiary Stricture(ECCBILE)(ECCBILE) | recruiting | — | 99 | Peking University Third HospitalOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06986486 | Liver Transplantation for Unresectable Perihilar Cholangiocarcinoma(pCOLA) | recruiting | — | 8 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 23, 2025 | clinicaltrials |
| NCT06406816 | Neoantigen Vaccine Plus Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma After Radical Resection | recruiting | Early Phase 1 | 10 | Yongyi ZengOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06914648 | The Dragon PLC Trial (DRAGON-PLC) | recruiting | N/A | 358 | Maastricht UniversityOTHER | 12 | May 15, 2025 | clinicaltrials |
| NCT06438822 | Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma | recruiting | Phase 2 | 51 | West China HospitalOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06956716 | Personalized Tumor Neoantigen mRNA Therapy for Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 1 / Phase 2 | 30 | Zhejiang UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT04037007 | Efficacy of Fistulotomy for Biliary Cannulation | recruiting | N/A | 320 | Coordinación de Investigación en Salud, MexicoOTHER_GOV | 1 | May 1, 2025 | clinicaltrials |
| NCT05065957 | Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer | recruiting | Phase 2 / Phase 3 | 180 | InnoPharmax Inc.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06583993 | A Clinical Trial Evaluating the Safety and Efficacy of Intravenous HNF4α srRNA in Treating Advanced ICC Patients | recruiting | Early Phase 1 | 9 | Shanghai Changzheng HospitalOTHER | 1 | Apr 24, 2025 | clinicaltrials |
| NCT05342194 | Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study | recruiting | Phase 3 | 480 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06355427 | The Effect of [18F] F-FAPI PET-CT on Management in Patients With Proximal Cholangiocarcinoma(FAPIChol) | recruiting | Phase 2 / Phase 3 | 81 | Mara Veenstra, MDOTHER | 1 | Apr 11, 2025 | clinicaltrials |
| NCT06860477 | Cryoablation Combined With Lenvatinib Plus Tislelizumab Compared With FOLFOX in Patients With Advanced Intrahepatic Cholangiocarcinoma (CASTLE-ZS-01) | recruiting | Phase 2 | 92 | Fudan UniversityOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06899854 | Collection of Blood and Tissue Samples From Patients With Primary Liver Cancer. | recruiting | — | 53 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | Apr 3, 2025 | clinicaltrials |
| NCT06620848 | A Study of HRS-4642 Monotherapy or in Combination With Adebrelimab in the Treatment of Advanced Biliary Tract Tumors. | recruiting | Phase 2 | 49 | Shanghai Zhongshan HospitalOTHER | 1 | Apr 2, 2025 | clinicaltrials |
| NCT05784688 | Study of TU2218 in Combination With KEYTRUDA®(Pembrolizumab) in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 140 | TiumBio Co., Ltd.INDUSTRY | 2 | Mar 30, 2025 | clinicaltrials |
| NCT05551299 | Treatment of Non-resectable Bile Duct Cancer with Radiofrequency Ablation or Photodynamic Therapy(CARP) | recruiting | Phase 4 | 258 | University of LeipzigOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT06864195 | A Simple Breath Test to Detect Liver Cancer and Monitor Liver Conditions(VOCAL2) | recruiting | — | 750 | Imperial College LondonOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06862934 | Liver Transplantation for Unresectable Intrahepatic Colangiocarcinoma After Sustained Response to Neoadjuvant Treatments(iCOLA) | recruiting | — | 14 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT06208462 | Neoadjuvant Therapy of HAIC(GEMOX) Combined With Adebrelimab and Lenvatinib for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | recruiting | Phase 2 | 33 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06852287 | Phase II Clinical Study of GemOX Hepatic Arterial Infusion Combined with Lenvatinib and Toripalimab for Advanced and Unresectable Intrahepatic Cholangiocarcinoma and Gallbladder Cancer(GOLD-HAIC) | recruiting | Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04299581 | Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT04954781 | TACE Combined With Tislelizumab in Patients With Advanced Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05010681 | Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer | recruiting | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT06849193 | Dynamic Prediction Model for Patients with Unresectable Biliary Malignancies Receiving Systemic Chemotherapy Combined with Immunotherapy: a Multicenter, Observational Study(BTCICTY-001) | recruiting | — | 332 | Zhongda HospitalOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05520788 | Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing(CCGLC-006) | recruiting | — | 200 | Tongji HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05557578 | GOT Applied As Neoadjuvant Regimen for Patients of Resectable ICC with High-risk Factors of Recurrence(GOT) | recruiting | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT05532059 | Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin (GPLET) in Patients with Advanced Cholangiocarcinoma | recruiting | Phase 2 | 100 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06139042 | Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers | recruiting | — | 1,608 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06718257 | Chemotherapy Combined with Immunotherapy and Targeted Therapy in Cholangiocarcinoma | recruiting | — | 300 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 6, 2025 | clinicaltrials |
| NCT05222971 | Olaparib With or Without Durvalumab for DDR Gene Mutated Biliary Tract Cancer Following Platinum-based Chemotherapy(OPTIMUM) | recruiting | Phase 2 | 62 | Asan Medical CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT06607276 | Phase 2 Trial of Adjuvant Adebrelimab Combined With Capecitabine in High-Risk Resected Cholangiocarcinoma: ACHIEVE(ACHIEVE) | recruiting | Phase 2 | 122 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT06664021 | Exploring the Efficacy and Safety of Tislelizumab in Combination With S-1 in the Treatment of Patients With Postoperative Recurrent High-risk Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 60 | Anhui Provincial HospitalOTHER_GOV | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06653127 | Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Biliary Tract Cancer Recurrence Surveillance(CCGLC-016) | recruiting | — | 50 | Tongji HospitalOTHER | 1 | Dec 30, 2024 | clinicaltrials |
| NCT06749730 | Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract Carcinoma | recruiting | Phase 2 | 63 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 27, 2024 | clinicaltrials |
| NCT06721286 | Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 70 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT06711211 | Spanish Registry of Digestive Tumours RETUD(RETUD) | recruiting | — | 20,000 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT06708858 | Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer | recruiting | Phase 2 | 35 | Dai, GuanghaiOTHER | 1 | Nov 27, 2024 | clinicaltrials |
| NCT05321992 | Evaluating a Community-Based Behaviour Change Communication Model to Prevent Cholangiocarcinoma in Khon Kaen, Thailand(eCHEC) | recruiting | N/A | 480 | McMaster UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06341764 | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma | recruiting | Phase 2 | 38 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06611345 | A Study of Tumor-Treating Fields in Combination With Durvalumab and Gemcitabine/Cisplatin in Biliary Tract Cancers | recruiting | N/A | 60 | Jiangsu Healthy Life Innovation Medical Technology Co., LtdINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT04183712 | Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA | recruiting | Phase 2 | 102 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05404347 | NGS in Gallbladder Cancer and Response to Treatment | recruiting | — | 100 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06298968 | Combined Therapy Using Gemcitabine and Cisplatin Chemotherapy, Lenvatinib and Adebrelimab for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 38 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT04340986 | Cohort of Patients With Hepatocellular Carcinoma or Cholangiocarcinoma(CHC/CC) | recruiting | — | 1,250 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT02920554 | The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer | recruiting | N/A | 88 | Saint Vincent's Hospital, KoreaOTHER | 1 | May 22, 2024 | clinicaltrials |
| NCT06296563 | Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAIC | recruiting | Phase 2 | 20 | Lei ZHAOOTHER | 1 | Apr 17, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jun 17, 2025source: clinicaltrials